GZMB and urinary bladder carcinoma: In conclusion, our discovery of Sweet-P targeting GRβ in bladder cancer sheds light on a novel drug therapy that specifically targets a gene known to cause growth, proliferation, migration, and GC hormonal therapy resistance.